INTRODUCTION {#S1}
============

The retinoblastoma tumor suppressor gene [RB]{.ul} is mutated in approximately 30% of all human cancers and in more than 90% of retinoblastomas, osteosarcomas and small cell lung carcinomas ([@R26]). pRB belongs to the family of pocket proteins that includes p107 and p130. These two proteins share structural and functional similarities with pRB, but are rarely mutated in human tumors ([@R5]; [@R27]). A large part of the tumor suppressor activity of pRB derives from its ability to interact with the E2F transcription factors and, together with the other pocket proteins, control the balance between quiescence and proliferation ([@R10]). E2Fs control the expression of genes crucial for cell cycle re-entry, DNA replication and mitosis. pRB binds to the E2Fs in its active under-phosphorylated form, and inhibits the transcription of E2F target genes through two distinct mechanisms ([@R6]; [@R24]). The first involves sequestration of E2F1, 2, and 3, and inhibition of their transcriptional activity, thereby preventing progression from the G1 to the S phase of cell cycle. The second involves formation of E2F4- or E2F5-pocket protein complexes that bind to E2F-responsive promoters and actively repress their transcription, thereby promoting quiescence. Consistent with these dual roles, [Rb^-/-^;p107^-/-^;p130^-/-^]{.ul} ([@R2]; [@R22]) and [E2f4^-/-^;E2f5^-/-^]{.ul} ([@R9]) mouse embryonic fibroblasts (MEFs) fail to respond to a variety of growth inhibitory signals, while MEFs lacking [E2f1]{.ul}, [E2f2]{.ul}, and/or [E2f3]{.ul} have impaired proliferative capacity ([@R13]; [@R29]). While these results have led to the designation of E2F1, E2F2 and E2F3 as "activators" and E2F4 and E2F5 as "repressors", accumulating evidence suggest that this division is not so clear-cut especially with regard to E2F4.

E2F4 is ubiquitously expressed throughout cell cycle, and accounts for most of the E2F endogenous activity ([@R17]). E2F4 has a transactivation domain but it is primarily localized to the cytoplasm in its free form due to the presence of strong nuclear export signals and thus its transcriptional activity is restrained ([@R8]; [@R25]). In the G0/G1 phase of cell cycle E2F4, by virtue of its interaction with the pocket proteins, accumulates in the nucleus where chromatin immunoprecipitation studies suggest that these E2F/pocket protein complexes play a major role actively repressing E2F-target genes by recruiting histone deacetylases ([@R19]; [@R21]). In agreement with a function of E2F4 in the G0/G1 phase of cell cycle, [E2f4]{.ul} null mice often die shortly after birth with defects in terminal differentiation including craniofacial, respiratory epithelium abnormalities and altered hematopoietic lineages that may result from an inability to establish quiescence ([@R12]; [@R20]). Concordantly, [E2f4^-/-^;E2f5^-/-^]{.ul} MEFs have a normal proliferation capacity but are unable to arrest in G1 in response to growth inhibitory signals ([@R9]). These observations all fit with the hypothesis that E2F4 is a repressive E2F. However, analysis of E2F's role in the context of [Rb]{.ul} mutant tumors challenges this conclusion. [Rb^+/-^]{.ul} mice die from intermediate lobe pituitary tumors and develop c-cell thyroid tumors at high frequency ([@R1]; [@R14]). Loss of [E2f4]{.ul} suppresses development of both tumor types and thus, significantly expands the lifespan ([@R15]). There are a number of possible explanations for E2F4 apparent oncogenic activity. First, E2F4 could behave as a trascriptional activator in the context of these tumor cells. Second, there is evidence that E2F4 may influence tumorigenesis in a indirect manner: we found that the absence of E2F4 in [Rb^-/-^]{.ul} cells allows p107 and p130 to associate with E2F1, E2F2 and E2F3 and presumably substitute for pRB in preventing these activator E2Fs from promoting proliferation and therefore tumorigenesis ([@R15]). Third, as the [Rb^+/-^;E2f4^-/-^]{.ul} germline mouse model requires [Rb]{.ul}-loss of heterozygosity (LOH) for tumorigenesis, it is possible that [E2f4]{.ul}-deficiency reduces the frequency of [Rb]{.ul} LOH or the viability of the resulting [Rb^-/-^;E2f4^-/-^]{.ul} cells. Finally, in the [Rb^+/-^;E2f4^-/-^]{.ul} animals, tumor onset is analyzed not in a wildtype context, but in tissues lacking [E2f4]{.ul}, a situation that does not reflect the normal tumor environment and may cause non-cell autonomous effects on [Rb]{.ul}-deficient tumor growth. These four models are not mutually exclusive.

To analyze tumorigenesis induced by combined loss of [E2f4]{.ul} and [Rb]{.ul}, in this study we generate [Rb^-/-^;E2f4^-/-^]{.ul} chimeric mice. This model system overcomes the lethality of the [Rb^-/-^;E2f4-/-]{.ul} germline animals and therefore eliminates the requirement for [Rb]{.ul} LOH. Moreover, the stochastic nature of the chimeric system allows for studying the effects of gene mutation in a wildtype context and importantly, due to its mosaic nature, to identify phenotypes that would unlikely be uncovered by the use of a tissue-specific conditional system. Consistent with previous observations in [Rb^+/-^;E2f4^-/-^]{.ul} germline animals, we found that loss of [E2f4]{.ul} suppresses formation of pituitary tumors that are the predominant cause of death of the [Rb^-/-^]{.ul} chimeras ([@R18]; [@R28]) and therefore greatly expands the lifespan. This extended longevity allowed the identification of two novel tumor types, ganglionic neuroendocrine neoplasms and papillary urethelial carcinomas. Altogether our observations indicate that E2F4 and pRB functionally interact in specific neuroendocrine tissues and establish a role for these proteins in the urogenital epithelium.

RESULTS {#S2}
=======

Isolation of mutant E2f4^-/-^;Rb^-/-^ ES cells and analysis of their contribution to embryonic and adult tissues {#S3}
----------------------------------------------------------------------------------------------------------------

We have previously shown that [E2f4]{.ul}-loss suppresses the formation of pituitary and thyroid tumor in [Rb^+/-^]{.ul} germline animals ([@R15]). To study the contribution of [E2f4]{.ul} to the tumors that arise in [Rb]{.ul} null tissues, we generated [E2f4^-/-^;Rb^-/-^]{.ul} chimeric mice. To obtain these animals, we intercrossed [E2f4^+/-^;Rb^+/-^ Rosa26]{.ul} germline mutant animals and isolated [E2f4^-/-^;Rb^-/-^Rosa26]{.ul} embryonic stem (ES) cells by [de novo]{.ul} derivation. Two [E2f4^-/-^;Rb^-/-^ Rosa26]{.ul} ES cell lines were injected into blastocysts giving rise to [E2f4;Rb]{.ul} chimeras. We screened E18.5 stage embryos for the presence of β-galactosidase activity (expressed from the [Rosa26]{.ul} allele) and found that both cell lines were able to contribute to the entire embryo with high efficiency indicating that the ES cells were pluripotent ([Figure 1a](#F1){ref-type="fig"}, data not shown). [E2f4^-/-^;Rb^-/-^]{.ul} ES cells also contributed to a variety of adult tissues ([Figure 1b](#F1){ref-type="fig"}, data not shown). However, we observed that on average, our cohort of adult [Rb^-/-^;E2f4^-/-^]{.ul} chimeric animals, had a lower degree of chimerism than the [Rb^-/-^]{.ul} chimeric mice as judged by coat color ([Table 1](#T1){ref-type="table"}, [@R18]). Since our [Rb^-/-^;E2f4^-/-^]{.ul} ES cells are pluripotent, and we know that [E2f4^-/-^]{.ul} animals can be viable ([@R12]; [@R20]), these findings suggest that additional loss of [E2f4]{.ul} decreases the viability of [Rb^-/-^]{.ul} cells in chimeric mice.

E2f4-loss suppresses pituitary tumors in Rb^-/-^ chimeric mice {#S4}
--------------------------------------------------------------

To study the effects of [E2f4]{.ul}-loss in [Rb]{.ul} tumorigenesis we aged our cohort of [Rb^-/-^;E2f4^-/-^]{.ul} chimeric animals and compared them to [Rb^-/-^]{.ul} chimeric mice that we generated in parallel ([@R18]). We found a striking difference in the lifespan of the [Rb^-/-^;E2f4^-/-^]{.ul} versus [Rb^-/-^]{.ul} chimeras. [Rb^-/-^]{.ul} chimeric animals die by the age of 9 months due to pituitary tumors ([@R18]). In stark contrast, after nine months more than 70% of the [Rb^-/-^;E2f4^-/-^]{.ul} chimeras were still alive ([Figure 2a, b](#F2){ref-type="fig"}). Accordingly, we found that less than half of the [Rb^-/-^;E2f4^-/-^]{.ul} chimeric mice developed pituitary tumors and the affected animals were all greater than ten months of age ([Figure 2b](#F2){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). Histologically, the pituitary tumors that do develop in the [Rb^-/-^;E2f4^-/-^]{.ul} animals are similar to the ones found in the [Rb^-/-^]{.ul} chimeras. They originate from the [pars intermedia]{.ul} of the pituitary, have the morphology of adenocarcinomas, and all derive from [Rb^-/-^;E2f4^-/-^]{.ul} mutant cells as shown by β-galactosidase staining ([Figure 3a, b](#F3){ref-type="fig"}). Thus, [E2f4]{.ul}-loss does not change the nature of the pituitary tumors that arise in the [Rb^-/-^]{.ul} chimeric mice, but rather delays their development and decreases their incidence. Analysis of pituitary tumor samples recovered from [Rb^-/-^]{.ul} and [Rb^-/-^;E2f4^-/-^]{.ul} chimeras at necropsy showed that there was a general absence of both apoptotic and proliferative cells (as judged by staining for TUNEL and Ki67 respectively) in both genotypes (data not shown). Thus, it remains an open question how E2F-4 loss suppresses pituitary tumor development. Since we detect pituitary tumors in [Rb]{.ul}-deficient mice with chimerism as low as 5% ([@R18]), we can be sure that the suppression of tumor development in [Rb^-/-^;E2f4^-/-^]{.ul} chimeras is not merely the result of insufficient contribution of [Rb^-/-^;E2f4^-/-^]{.ul} cells to the pituitary. Thus, we can now conclude that the effect of [E2f4]{.ul}-loss on the development of tumors in this organ is not due to a change in the propensity of [Rb]{.ul} LOH.

Differential effects of E2f4-deficiency in other Rb-dependent neuroendocrine tumors {#S5}
-----------------------------------------------------------------------------------

[E2f4]{.ul}-loss has been shown to completely suppress c-cell carcinomas of the thyroid in [Rb^+/-^;E2f4^-/-^]{.ul} germline mice ([@R15]). These tumors arise at high frequency in [Rb^+/-^]{.ul} germline mice, but are less commonly detected in [Rb^-/-^]{.ul} chimeras where only a minority of the animals shows these neoplastic lesions ([Table 1](#T1){ref-type="table"}, [@R18]). When we screened [Rb^-/-^;E2f4^-/-^]{.ul} chimeric animals, we found that they also bore thyroid tumors at a similar frequency to [Rb^-/-^]{.ul} chimeras ([Figure 4a](#F4){ref-type="fig"}, [Table 1](#T1){ref-type="table"}) leading us to conclude that [E2f4]{.ul} is dispensable for the development of c-cell tumors in [Rb^-/-^]{.ul} chimeric thyroids. This is in contrast to the suppression of thyroid tumors that occurs in the germline [Rb^+/-^;E2f4^-/-^]{.ul} animals suggesting that this latter phenotype is likely due to a change in the rate of [Rb]{.ul} LOH, or to non-cell autonomous effects caused by the lack of [E2f4]{.ul} in other tissues.

[Rb^-/-^]{.ul} chimeras develop additional neuroendocrine lesions in adrenal glands and in the lung ([@R18]; [@R28]). We therefore also examined these organs in the [Rb^-/-^;E2f4^-/-^]{.ul} chimeric mice at the histological level. We observed that these animals presented uni- or multifocal foci of hyperplasia in the adrenal medulla (pheochromocytoma) at a similar frequency to [Rb^-/-^]{.ul} chimeras ([Figure 4b](#F4){ref-type="fig"}, [Table 1](#T1){ref-type="table"}), indicating that [E2f4]{.ul} is also dispensable for this tumor type. Notably, we observed a very different effect in the lung. We have previously observed neuroendocrine cell hyperplasia in the lung of 10 out of 13 [Rb^-/-^]{.ul} chimeras ([@R18]). We found that [Rb^-/-^;E2f4^-/-^]{.ul} chimeric animals also presented hyperplastic areas in the lung, but the severity of these lesions as well as the percentage of animals bearing them, was much lower when compared to than seen in the [Rb^-/-^]{.ul} chimeras ([Figure 4c](#F4){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). Thus, our findings suggest that [E2f4]{.ul}-loss has differential effects in a variety of [Rb]{.ul}-deficient neuroendocrine tumors. It is dispensable for adrenal gland and thyroid tumors, while playing an essential role in pituitary tumors and in [Rb^-/-^]{.ul} pulmonary neuroendocrine cells.

Novel tumor phenotypes in Rb^-/-^;E2f4^-/-^ chimeras {#S6}
----------------------------------------------------

The increased lifespan of the [Rb^-/-^;E2f4^-/-^]{.ul} animals due to suppression of pituitary tumors, together with the ability to generate adult tissues simultaneously lacking [Rb]{.ul} and [E2f4]{.ul}, gave us the unique opportunity to identify new tumor types that might be modulated by these proteins. We performed necropsy and whole histology on all the [Rb^-/-^;E2f4^-/-^]{.ul} chimeric mice and found a distinct tumor spectrum in the older animals ([Table 1](#T1){ref-type="table"}). Six mice, all but one older than ten months, showed neoplastic lesions within the ganglia in different areas of the body such as the neck, kidney region and testes. These lesions appeared to be composed by groups of very dark cells embedded within neurons whose morphology was reminiscent of neuroendocrine cells ([Figure 5a](#F5){ref-type="fig"}). To confirm that these cells were indeed of neuroendocrine origin, we performed immunohistochemistry for the markers GCRP and Synaptophysin and found that all of them were positive ([Figure 5a](#F5){ref-type="fig"}). As neuroendocrine cells are not normally detected within ganglia we looked for any sign of metastases originating from other neuroendocrine tumors present in these animals, but were unable to find any. This suggests that these cells were indeed arising from within the ganglia. We did not detect any TUNEL-positive cells in the neoplastic lesions of the [Rb^-/-^;E2f4^-/-^]{.ul} chimeras or the normal ganglia of either Rb^-/-^ or [Rb^-/-^;E2f4^-/-^]{.ul} chimeras (data not shown). Thus, we have no evidence that [E2f4]{.ul}-deficiency acts to suppress the induction of apoptosis by [Rb]{.ul}-loss, but these negative data do not rule this out. We also did not detect any Ki67-positive cells in either the neoplastic or normal [Rb^-/-^;E2f4^-/-^]{.ul} chimeric ganglia (data not shown). Thus, it remains an open question whether the ganglionic tumors result from a direct effect (e.g. via differences in proliferative and/or apoptotic capacity of [Rb^-/-^;E2f4^-/-^]{.ul} versus [Rb]{.ul} mutant tissues) or an indirect effect (the extended lifespan of the Rb mutant chimeras) of [E2f4]{.ul} loss.

In addition to these ganglionic neoplasms, we also identified tumors in the urogenital epithelium of the [Rb^-/-^;E2f4^-/-^]{.ul} chimeric mice ([Table 1](#T1){ref-type="table"}). We noticed that three animals, 16 months of age or older, had polyps within the uroepithelium that lines the ureter. This papillary form of urothelial cancer was hyperplastic non invasive in two animals, but highly dysplastic and invasive in a third animal ([Figure 5b](#F5){ref-type="fig"}). The severity of these lesions prevented normal exchange of urine between the kidney and the bladder causing nephrosis (not shown). Urothelial cancer does not spontaneously arise in mice and there is no evidence of this tumor in [Rb^-/-^]{.ul} chimeras ([@R18]; [@R28]). Histological comparison of tumorigenic versus normal urothelium in the [Rb^-/-^;E2f4^-/-^]{.ul} chimeras, revealed no apoptosis, but high levels of proliferation specifically within circumscribed regions of the tumors but not the normal urothelium (data not shown). Thus, as above, these studies provide no evidence for, but also do not rule out, the possibility that E2f4-loss plays a direct role in promoting formation of these tumors.

Finally, we wished to determine if urothelium and ganglionic neoplasms were cell or non-cell autonomous. As we could not take advantage of β-galactosidase staining due to problems of high background (kidney) or poor penetrability of the dye (ganglion) in the tissues surrounding the tumors, we assessed the contribution of mutant cells to the novel tumors by screening the tumor areas for the presence of the [E2f4]{.ul} mutant allele. The mutant band was clearly present in both neoplasms and its intensity, relative to the wildtype band, correlated well with the heterogeneity of the tumors ([Figure 5c](#F5){ref-type="fig"}). Specifically, the mutant band was relatively weak in the urothelium neoplasm which had a high non-epithelial component and much stronger in the ganglionic neoplasm which was more homogenous. Although correlative, these results strongly suggest that these novel tumor types are derived from the [Rb^-/-^;E2f4^-/-^]{.ul} cells. Similar to the ganglionic neurendocrine neoplasms, urothelial cancer was found at a time when the vast majority of [Rb^-/-^]{.ul} chimeric animals are dead. Thus, it is an open question whether these tumor types arise as a consequence of loss of both [Rb]{.ul} and [E2f4]{.ul} or whether they can arise with long latency through inactivation of [Rb]{.ul} in an [E2f4]{.ul}-independent manner. Nevertheless, the finding that [Rb^-/-^;E2f4^-/-^]{.ul} chimeric mice develop a papillary form of urothelial cancer represents the first direct evidence of a role for [Rb]{.ul} in this cancer type and is concordant with the high incidence of [Rb]{.ul} mutation in urothelial carcinoma of the bladder.

DISCUSSION {#S7}
==========

pRB's prominent role in tumorigenesis is due, at least in part, to its ability to bind the E2Fs and control cell division. Nevertheless, the extent to which the interaction of pRB with the E2Fs influences its role in cancer remains unclear due in part to the embryonic lethality of [Rb^-/-^]{.ul} and [Rb^-/-^;E2f^-/-^]{.ul} mutant animals. In this study we generated [Rb^-/-^;E2f4^-/-^]{.ul} chimeric mice to analyze the interplay between pRB and E2F4. These animals are viable at levels of chimerism up to 60% thus allowing us to study the contribution of [E2f4]{.ul} to [Rb]{.ul}-dependent tumorigenesis. [Rb^-/-^]{.ul} chimeric mice die of pituitary tumors between 2 and 9 months of age ([@R18]; [@R28]). We found that loss of [E2f4]{.ul} increased the lifespan of these animals by delaying the development and decreasing the incidence of pituitary tumors. Therefore, our studies show conclusively that [E2f4]{.ul}-loss inhibits pituitary tumors independently of the rate of [Rb]{.ul} LOH. Furthermore, the ability to generate mice with a wide range of chimerism allows us to extrapolate that the suppressive effect of [E2f4]{.ul} on this tumor type is cell autonomous as we could detect pituitary tumors in [Rb]{.ul} null mice with chimerism as low at 5% ([@R18]). The function of E2F4 in cell division is thus still unclear; [in vitro]{.ul} E2F4 acts as a proliferation inhibitor, while [in vivo]{.ul} E2F4 functions to promote pituitary tumorigenesis. We believe that two models may reconcile these results. The first, called the "pocket protein reshuffling" model, stems from our finding that p107 and p130, normally unable to bind to the activator E2Fs, associate with these proteins in [Rb;E2f4]{.ul} deficient tissues ([@R15]). These novel repressor complexes could prevent E2F1, E2F2 and E2F3 from activating target genes responsible for cell proliferation thus inhibiting tumor formation in [Rb^+/-^;E2f4^-/-^]{.ul} mice. The second model proposes that E2F4 functions as a transcriptional activator in certain contexts, including [Rb]{.ul} mutant tumors, and this explains its oncogenic activity. E2F4 does in fact have a strong activation domain and it is certainly capable of activating E2F responsive promoters when localized to the nucleus by over-expression or addition of nuclear localization signals ([@R3]; [@R25]). Notably, we have recently found that E2F4 associates with the promoter of E2F-responsive genes in tumor cells, concordant with their transcriptional activation, raising support for this hypothesis (Iaquinta and J. A. L., unpublished). Based on our [in vivo]{.ul} observations ([@R15]; Iaquinta and J. A. L., unpublished), we suspect that both the pocket protein reshuffling and transcriptional activation mechanisms contribute to E2F4's oncogenic properties. Our chimeric system does not address these two possibilities, and additional experiments will be required to tease out the underlying mechanisms.

Our data also show that [Rb^-/-^]{.ul} and [Rb^-/-^;E2f4^-/-^]{.ul} chimeric mice developed thyroid tumors at a similar frequency. This is in contrast to what previously found in [Rb^+/-^;E2f4^-/-^]{.ul} germline animals where the thyroid tumors are fully suppressed ([@R15]). It is hard to envisage how either the reshuffling or transcriptional activation mechanisms could account for tumor suppression in [Rb^+/-^;E2f4^-/-^]{.ul} germline mice, but not in [Rb^-/-^;E2f4^-/-^]{.ul} chimeras. Thus, two possibilities remain to explain the specific suppression of tumors in the [Rb^+/-^;E2f4^-/-^]{.ul} thyroids. One is that [E2f4]{.ul}-deficiency may decrease the rate of [Rb]{.ul} LOH in the c-cells of [Rb^+/-^]{.ul} mice. The other is that cell non-autonomous effects may operate in [Rb^+/-^;E2f4^-/-^]{.ul} germline. These current and past findings highlight the utility of employing chimeric mouse models to identify direct requirements for particular E2Fs in tumorigenesis. Interpretation of data generated in traditional germline mice is confounded by possible non-cell autonomous effects as well as a requirement for [Rb]{.ul} LOH. In fact, while previous [Rb;E2f]{.ul} germline mutant mice assigned opposing roles for [E2f3]{.ul} and [E2f4]{.ul} in the development of thyroid tumors ([@R15]; [@R32]) our studies in chimeric mice suggest that these [E2fs]{.ul} are both fully dispensable for this tumor type ([@R18]).

Irrespective of the mechanisms that operate in the pituitary and the thyroid, [Rb^-/-^;E2f4^-/-^]{.ul}chimeric mice allowed the examination of the effects that [E2f4]{.ul}-loss has on other tumor types present in [Rb^-/-^]{.ul} chimeras. These animals develop neuroendocrine lesions in the adrenal gland and in the lung ([@R18]; [@R28]) and we find that [E2f4]{.ul} differentially affects these tumor types. It is dispensable for the adrenal gland tumors, while is required for the hyperplasia of the neuroendocrine cells. The latter lesions are believed to be the precursors of small cell lung carcinomas, a highly metastatic and therefore lethal tumor type ([@R16]). Therefore, our findings indicate that [E2f4]{.ul} may play a role in the hyperplastic stage of small cell lung carcinomas. Interestingly this property is not unique to E2F4 as [Rb^-/-^;E2f3^-/-^]{.ul} chimeric mice have no detectable signs of neuroendocrine lung hyperplasia ([@R18]). Thus, this suggests that E2F3 and E2F4 play a prominent role in the hyperplastic stage of small cell lung carcinoma. As with the pituitary, The E2F4's oncogenic function could result from the "pocket protein reshuffling" and/or the "activating" function mechanisms described above.

The extended longevity of [Rb^-/-^;E2f4^-/-^]{.ul} chimeric mice due to suppression of pituitary tumors allowed us to identify two novel tumor types in these mice, ganglionic neuroendocrine neoplasms and urethelial cancer. The presence of ectopic neuroendocrine cells within ganglions confirms once more that [Rb]{.ul} plays a key role in neuroendocrine lineage, which include all the tumor types listed above, and has very interesting implications for the biology of these cells. During development neuroendocrine and neuronal cells share a common progenitor, called sympathoadrenal cells that originate from the neural crest ([@R11]). This progenitor cell migrates from the dorsal aorta to its final destination where it adopts either a neuronal or neuroendocrine fate. The mature neuroendocrine cells maintain the expression of markers specific of the immature common progenitors while the mature neurons downregulate these markers. Thus, we speculate that the neuroendocrine-like neoplastic cells that we found within the ganglia of [Rb^-/-^;E2f4^-/-^]{.ul} chimeras are not derived from neurendocrine cells, but represent immature, neural crest-like stem cells that either failed to differentiate into neurons or represent a physiological population of neuronal stem cells that proliferate inappropriately. Unfortunately, to our knowledge there are no markers that discriminate between a blastic stage neuronal cell and a differentiated neuroendocrine cell, and would therefore allow us to show that the lesions found in the ganglia of [Rb^-/-^;E2f4^-/-^]{.ul} chimeras are neuronal stem cell-like cells. Nevertheless, as the determinant factors that govern the fate choice are still not well understood, our findings suggest that [Rb]{.ul} and [E2f4]{.ul} play a role in the development of the neuronal-neuroendocrine cells and may potentially add another tile to the complex mosaic that specifies the sympathoadrenal lineage.

The other novel tumor in [Rb^-/-^;E2f4^-/-^]{.ul} chimeric animals is urothelial transitional cell carcinoma. Urothelial carcinomas are tumors of the urogenital tract and represent the fifth most common cancer type in humans ([@R4]). They manifest as two variants, papillary or non-papillary. The papillary form accounts for about 80% of urethelial cancers, is generally low grade and has been documented to give rise to invasive transitional cell carcinoma in 15% of cases of human bladder cancers. The non papillary transitional cell carcinoma, is high grade, accounts for the remaining 20% cases of human urethelial carcinomas, and originates [de novo]{.ul} or from preexisting carcinoma [in situ]{.ul}. The observation that this non papillary form is present in patients with no previous history of papillary carcinomas, and the fact that the non papillary and papillary forms have a distinct genetic signature, has lead to the hypothesis that these two types of transitional cell carcinoma are unrelated ([@R30]; [@R23]). There is a strong correlation between [Rb]{.ul} mutations and urothelial cancer. In humans [Rb]{.ul} has been found inactivated in about 60% cases of human bladder cancer, although there is still a debate as to whether [Rb]{.ul} mutation is associated with the low grade, non papillary form ([@R4]; [@R30]). Despite the strong association between [Rb]{.ul} mutations and urothelial cancer, only one animal model has investigated the role of pRB in this tumor type. In this mutant mouse [Rb]{.ul} and [p53]{.ul} are both inactivated in urothelial cells by transgenic expression of the SV40 Large T antigen ([@R31]), and this causes invasive carcinoma [in situ]{.ul}. In [Rb^-/-^;E2f4^-/-^]{.ul} chimeras we found both invasive and non invasive papillary carcinomas, suggesting that [Rb]{.ul} mutation may facilitate the switch from low grade to dysplastic, high grade tumors. Thus, together the Large T antigen and [Rb;E2f4]{.ul} mouse models recapitulate the non papillary and papillary variants of human transitional cell carcinomas and implicate a key role for [Rb]{.ul} in the development of these tumors.

To conclude, we have learnt from the analysis of [Rb^-/-^;E2f4^-/-^]{.ul} chimeric animal that [E2f4]{.ul} plays a role in the pituitary tumors as well as in lung neuroendocrine hyperplasia caused by loss of [Rb]{.ul}, but not in thyroid and adrenal gland tumors. In addition our chimeric mouse model gives us the opportunity to identify pRB and E2F unknown functions. We have shown here that [E2f4]{.ul} and [Rb]{.ul} have a role in derivatives of neural crest cells and in the urogenital epithelium. We are now pursuing the significance of these findings by generating [E2f4]{.ul} conditional mice. We will use these mice in combination with the [Rb]{.ul} conditional-urethelial or neural crest specific Cre-Recombinase expressing mice to dissect the relative roles of [Rb]{.ul} and [E2f4]{.ul} in these tissue types and to generate novel cancer mouse models.

MATERIAL AND METHODS {#S8}
====================

Generation of ES cells and chimeric animals {#S9}
-------------------------------------------

Mouse colonies were maintained in compliance with Institutional Animal Care and Use Committee guidelines. [E2f4]{.ul} and [Rb]{.ul} mutant mice, as well as the primers used for genotyping were previously described ([@R12]; [@R14]). [E2f4^+/-^Rb^+/-^]{.ul} 129/Sv mice were crossed to 129/Sv [Rosa β-geo 26 (Rosa26)]{.ul} animals ([@R7]). The [E2f4^+/-^Rb^+/-^ Rosa26]{.ul} mice so obtained were mated and the females sacrificed at 3.5 days post-coitum. ES cells were derived by E3.5 blastocysts as previously described ([@R18]). [E2f4^-/-^Rb^-/-^ Rosa26]{.ul} chimeric mice were generated by injecting 10-12 mutant ES cells into C57Bl/6 blastocysts.

Histology, immunohistochemistry and X-gal staining {#S10}
--------------------------------------------------

Tissues were processed for X-gal staining or directly fixed in phosphate-buffered formalin as previously described ([@R18]). To visualize the pituitary glands, adult heads were fixed for a week in Bouin's fixative. 5μm sections of paraffin embedded tissues were stained with H&E, or processed for immunohistochemistry. For antibody staining sections were processed as previously described ([@R18]) with 1:500 mouse anti-synaptophysin (Chemicon, clone SY38), and 1:5000 rabbit anti-neuroendocrine cell marker calcitonin-related peptide (anti-CGRP, Sigma). Antigen-antibody complexes were detected with diaminobenzidine (DAB).
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![[Rb^-/-^;E2f4^-/-^]{.ul} ES cells contribute to chimeric embryos and to adult tissues. (**a**) E18.5 [Rb^-/-^;E2f4^-/-^]{.ul} embryos stained for β-galactosidase activity (blue color) show high levels of chimerism. (**b**) [Rb^-/-^;E2f4^-/-^]{.ul} ES cells contribute to a wide variety adult tissues as shown by β-galactosidase activity (blue color) in representative examples.](nihms-72260-f0001){#F1}

![[E2f4]{.ul}-loss increases the lifespan of [Rb^-/-^]{.ul} chimeras by delaying the onset and the incidence of pituitary tumors. (**a**) Kaplan-Meyer curve showing a significant difference in survival of [Rb^-/-^;E2f4^-/-^]{.ul} versus [Rb^-/-^]{.ul} chimeras. (**b**) Schematic representation of the relations between percentage of chimerism, time of death and tumors found in [Rb^-/-^;E2f4^-/-^]{.ul} chimeric animals. Each chimeric animal is represented by a bar reporting the percent chimerism, and is arranged according to the time of death (from youngest to oldest, grey line, second Y axis). Animals presenting pituitary or thyroid tumors are indicated with (P) and (T) respectively. Note that the pituitary tumors manifest only after 10 month of age.](nihms-72260-f0002){#F2}

![The pituitary tumors that do develop in [Rb^-/-^;E2f4^-/-^]{.ul} chimeric pituitaries are morphologically similar to the ones that originate in [Rb^-/-^]{.ul} chimeras and exclusively derive from mutant cells. (**a**) Histological analysis of [Rb^-/-^]{.ul} and [Rb^-/-^;E2f4^-/-^]{.ul} pituitary tumors shows that these tumors are adenocarcinomas and arise from the intermediate lobe of the pituitary. (**b**) β-galactosidase staining (blue color) of pituitary tumors derived from [Rb^-/-^;E2f4^-/-^]{.ul} indicates that these tumors specifically derive from mutant cells.](nihms-72260-f0003){#F3}

![[E2f4]{.ul}-loss partially suppresses pulmonary neuroendocrine hyperplasia while being dispensable for thyroid and adrenal glands tumors that arise in [Rb^-/-^]{.ul} chimeras (a-c). H&E staining of sections containing the various neuroendocrine tumors found in [Rb^-/-^]{.ul} and [Rb^-/-^;E2f4^-/-^]{.ul} chimeric mice (**a**) c-cell carcinoma of the thyroid, (**b**) tumor in the adrenal gland medullaand (**c**) hyperplastic lung neuroendocrine cells also showing positivity for β-galactosidase activity (blue color).](nihms-72260-f0004){#F4}

![[E2f4]{.ul}-loss causes the appearance of novel tumors in [Rb^-/-^]{.ul} chimeric mice. (**a**) Ganglionic neuroendocrine neoplasms found in [Rb^-/-^;E2f4^-/-^]{.ul} chimeras. H&E staining of ganglia containing a very dark group of neuroendocrine-like cells in [Rb^-/-^;E2f4^-/-^]{.ul} chimeras (top left, asterisk) but not in [Rb^-/-^]{.ul} chimeras (top right). Bottom panel: examples of ganglionic neuroendocrine neoplasms (asterisks) showing strong positivity for the neuroendocrine marker GCRP and Synaptophysin. Note that the positivity to GCRP and Synaptophysin also extends to the neurons. (**b**) Loss of [E2f4]{.ul} leads to urothelium transitional cell carcinomas in [Rb^-/-^]{.ul} chimeric mice. Polyps originating from the urogenital epithelium protrude into the lumen of the ureter to give rise to non invasive (top panel) and invasive papillary carcinomas (middle panel) where the epithelium has penetrated the muscle wall (asterisks). The urothelium of [Rb^-/-^]{.ul} chimerics is completely normal (bottom panel). (**c**) The novel tumors derive from [Rb^-/-^;E2f4^-/-^]{.ul} cells. Top: PCR analysis of genomic DNA isolated from the ganglionic and urothelium tumors (shown below) and assayed for the presence of the mutant and wildtype allele of [E2f4]{.ul}. Note that the ganglionic lesion is very homogeneous compared to the urothelium polyps where the epithelium represents only a small fraction of the tumor.](nihms-72260-f0005){#F5}

###### 

Tumorigenic phenotypes in [Rb-/-]{.ul} versus [Rb-/-;E2f4-/-]{.ul} chimeric mice.

  ------------------------------------------------------------------------------------------------------
                                   [Rb^-/-^]{.ul} %, N animals   [Rb^-/-^;E2f4^-/-^]{.ul} %; N animals
  -------------------------------- ----------------------------- ---------------------------------------
  Average chimerism                62%; 13                       28%; 21

  Pituitary tumors                 69%; 13                       38%; 21

  Thyroid tumors                   31%; 13                       16%; 19

  Adrenal gland lesions            58%; 12                       67%; 18

  Pulmonary neuroendocrine cell\   77%; 13                       20%; 20
  hyperplasia                                                    

  Neuroendocrine ganglionic\       0%; 12                        30%; 20
  neoplasms                                                      

  Uroepithelium lesions            0%; 12                        15%; 20
  ------------------------------------------------------------------------------------------------------
